MX348337B - Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos. - Google Patents

Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.

Info

Publication number
MX348337B
MX348337B MX2013005820A MX2013005820A MX348337B MX 348337 B MX348337 B MX 348337B MX 2013005820 A MX2013005820 A MX 2013005820A MX 2013005820 A MX2013005820 A MX 2013005820A MX 348337 B MX348337 B MX 348337B
Authority
MX
Mexico
Prior art keywords
derived peptide
human lactoferrin
masking agent
active substance
lactoferrin derived
Prior art date
Application number
MX2013005820A
Other languages
English (en)
Other versions
MX2013005820A (es
Inventor
Windhab Norbert
Hartwig Benedikt
Tome Alcalde Juan
Del Pilar Ansuategui Panzano Maria
Javier Vara Carrera Matías
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2013005820A publication Critical patent/MX2013005820A/es
Publication of MX348337B publication Critical patent/MX348337B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un péptido derivado de lactoferrina humana para usarse como un agente de enmascaramiento de antígenos en la producción de una composición farmacéutica para el suministro de una sustancia biológicamente activa en un organismo mamífero, en donde la sustancia biológicamente activa es capaz de inducir una respuesta inmune no deseada por el organismo mamífero, en donde la composición farmacéutica comprende un agregado supramolecular de la sustancia biológicamente activa y el péptido derivado de lactoferrina humana, con el efecto de que después del suministro de la composición farmacéutica al organismo mamífero, no hay o sólo hay una inducción reducida de la respuesta inmune no deseada contra la sustancia biológicamente activa.
MX2013005820A 2010-11-26 2010-11-26 Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos. MX348337B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/068302 WO2012069089A1 (en) 2010-11-26 2010-11-26 Human lactoferrin derived peptide for use as an antigen masking agent

Publications (2)

Publication Number Publication Date
MX2013005820A MX2013005820A (es) 2013-07-12
MX348337B true MX348337B (es) 2017-06-07

Family

ID=43837881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005820A MX348337B (es) 2010-11-26 2010-11-26 Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.

Country Status (17)

Country Link
US (1) US9724422B2 (es)
EP (1) EP2643344B1 (es)
JP (1) JP6073239B2 (es)
KR (1) KR101765364B1 (es)
CN (1) CN103906760B (es)
AU (1) AU2010364538B2 (es)
BR (1) BR112013012811B8 (es)
CA (1) CA2818951C (es)
ES (1) ES2627960T3 (es)
HK (1) HK1196379A1 (es)
HU (1) HUE033501T2 (es)
IL (1) IL226198B (es)
MX (1) MX348337B (es)
PL (1) PL2643344T3 (es)
RU (1) RU2573422C2 (es)
SI (1) SI2643344T1 (es)
WO (1) WO2012069089A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767501T3 (es) 2014-05-28 2020-06-17 Evonik Operations Gmbh Nanopartícula
US11225520B2 (en) 2016-02-16 2022-01-18 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
DE102016008601B4 (de) 2016-07-14 2019-05-23 Giesecke+Devrient Currency Technology Gmbh Sicherheitselement mit reversibel veränderbarem Farbbereich
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN107226860B (zh) * 2017-07-06 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽skhssldcvl及其制备方法和应用
IL278469B2 (en) 2018-05-08 2024-02-01 Evonik Operations Gmbh A nanoparticle containing a bioresorbable polyester, a hydrophilic polymer, and an acylated human lactoferrin-derived peptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5977337A (en) 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US6423509B1 (en) 1998-07-15 2002-07-23 Samyang Genex Corporation Pichia pastoris strain for producing lactoferrin and methods of use
JP2000045182A (ja) * 1998-07-23 2000-02-15 Peptide Science:Kk 抗菌性繊維および繊維・皮革用抗菌加工剤
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
WO2004037073A2 (en) * 2002-10-25 2004-05-06 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
JP5264502B2 (ja) 2005-12-30 2013-08-14 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞透過性ペプチドとして使用できるペプチド

Also Published As

Publication number Publication date
CA2818951A1 (en) 2012-05-31
EP2643344B1 (en) 2017-03-22
KR101765364B1 (ko) 2017-08-08
RU2573422C2 (ru) 2016-01-20
KR20130119955A (ko) 2013-11-01
IL226198B (en) 2019-01-31
BR112013012811B8 (pt) 2022-07-05
ES2627960T3 (es) 2017-08-01
JP6073239B2 (ja) 2017-02-01
AU2010364538A1 (en) 2013-07-11
CA2818951C (en) 2018-03-13
AU2010364538B2 (en) 2016-04-14
CN103906760B (zh) 2017-02-22
BR112013012811A2 (pt) 2016-09-13
BR112013012811B1 (pt) 2021-07-06
HK1196379A1 (zh) 2014-12-12
RU2013128884A (ru) 2015-01-10
JP2014501723A (ja) 2014-01-23
WO2012069089A1 (en) 2012-05-31
EP2643344A1 (en) 2013-10-02
US20130302342A1 (en) 2013-11-14
US9724422B2 (en) 2017-08-08
CN103906760A (zh) 2014-07-02
HUE033501T2 (en) 2017-12-28
MX2013005820A (es) 2013-07-12
SI2643344T1 (sl) 2017-07-31
IL226198A0 (en) 2013-07-31
PL2643344T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
MX347504B (es) Formulaciones concentradas de proteina y usos de las mismas.
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
GB201201314D0 (en) Composition
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
IN2012MN02591A (es)
MX349004B (es) Nuevos compuestos.
SG178991A1 (en) Anti-gitr antibodies
GB201118656D0 (en) New compounds
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX340985B (es) Compuestos de n-heteroarilo.
MX2013005820A (es) Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
EE05760B1 (et) Ravimkoostis
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
MX2016008102A (es) Composiciones y métodos para tratar la acumulacion de tejido graso.
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
TN2014000498A1 (en) Pharmaceutical formulation
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.

Legal Events

Date Code Title Description
FG Grant or registration